Global Amyotrophic Lateral Sclerosis (ALS) Market, By Type (Sporadic ALS, Familial ALS), Treatment Type (Chemotherapy, Medication, Stem Cell Therapy, Physical Therapy, Respiratory Therapy, Speech Therapy, Others), Diagnosis (Electromyogram, MRI, Blood and Urine Tests, Spinal Tap, Muscle Biopsy), Symptoms (Cognitive Changes, Pain, Slurring of Speech, Fatigue, Difficulty Breathing and Swallowing Problems with Saliva and Mucus, Increased Clumsiness, Cramping and Twitching, Weakness, Difficulty Maintaining Good Posture, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Amyotrophic Lateral Sclerosis (ALS) Market
Amyotrophic lateral sclerosis (ALS) market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.13% in the above mentioned forecast period.
Amyotrophic lateral sclerosis (ALS) is also referred as Lou Gehrig's disease. It is a progressive neurodegenerative disease in which nerve cells in the central nervous system that regulate voluntary muscles are damaged. Muscle twitching, stiff muscles, and weakness owing to a decrease in the size of muscles in the legs or arms are some of the common symptoms of this disease. The most prevalent type of motor neuron disease is ALS, which causes the body's cells to deteriorate and die, leaving the brain unable to regulate voluntary movements. ALS patients may lose the ability to swallow, breathe, speak, walk, and use their hands in about half of the cases.
The rise in the prevalence of amyotrophic lateral sclerosis will act as major driver that will results in the expansion of market’s growth. Another significant factor influencing the growth rate of amyotrophic lateral sclerosis (ALS) market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, rising initiatives by public and private organisations to spread awareness and growing government funding are the factors that will expand the amyotrophic lateral sclerosis (ALS) market. Other factors such as increase in the demand for effective therapies and rising geriatric population will positively impact the amyotrophic lateral sclerosis (ALS) market’s growth rate. Additionally, high disposable income and inclination towards sedentary lifestyle will result in the expansion of amyotrophic lateral sclerosis (ALS) market.
Moreover, the rise in the research and development activities and launch of effective therapies will provide beneficial opportunities for the amyotrophic lateral sclerosis (ALS) market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate amyotrophic lateral sclerosis (ALS) market in future.
However, high cost associated with the treatment and lack of infrastructure in low-income countries will impede the growth rate of amyotrophic lateral sclerosis (ALS) market. Additionally, complications involved with the disease will hinder the amyotrophic lateral sclerosis (ALS) market growth. Less awareness and the dearth of technically skilled professionals will further challenge the market in the forecast period mentioned above.
This amyotrophic lateral sclerosis (ALS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Amyotrophic lateral sclerosis (ALS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Amyotrophic Lateral Sclerosis (ALS) Market Scope and Market Size
The amyotrophic lateral sclerosis (ALS) market is segmented on the basis of type, treatment type, diagnosis, symptoms, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the amyotrophic lateral sclerosis treatment market can be segmented into sporadic ALS and familial ALS.
- On the basis of treatment type, the amyotrophic lateral sclerosis treatment market can be segmented into chemotherapy, medication, stem cell therapy, physical therapy, respiratory therapy, speech therapy and others. The medication segment is further sub-segmented into riluzole, edaravone and nuedexta.
- Based on diagnosis, the amyotrophic lateral sclerosis treatment market can be segmented into electromyogram, MRI, blood and urine tests, spinal tap, muscle biopsy.
- Based on symptoms, the amyotrophic lateral sclerosis treatment market can be segmented into cognitive changes, pain, slurring of speech, fatigue, difficulty breathing and swallowing problems with saliva and mucus, increased clumsiness, cramping and twitching, weakness, difficulty maintaining good posture, Others
- On the basis of end-users, the amyotrophic lateral sclerosis (ALS) market is segmented into clinic, hospital and others.
- The amyotrophic lateral sclerosis (ALS) market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Amyotrophic Lateral Sclerosis (ALS) Market Country Level Analysis
Amyotrophic lateral sclerosis (ALS) market is analyzed and market size information is provided by the country, type, treatment type, diagnosis, symptoms, end-users and distribution channel as referenced above.
The countries covered in the amyotrophic lateral sclerosis (ALS) market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the amyotrophic lateral sclerosis (ALS) market due to the presence of major key players, favourable reimbursement policies and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Amyotrophic lateral sclerosis (ALS) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Amyotrophic Lateral Sclerosis (ALS) Market Share Analysis
Amyotrophic lateral sclerosis (ALS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to amyotrophic lateral sclerosis (ALS) market research.
Some of the major players operating in the amyotrophic lateral sclerosis (ALS) market are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi, Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, Apotex Inc, Neuralstem, Inc., Implicit Bioscience, F. Hoffmann-La Roche Ltd, AB Science, and ADVANZ PHARMA, among others.
SKU-